drugset
drugset / Trial / NCT06705088

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants

NCT06705088 ↗

Phase 1 Completed 64 enrolled Suven Life Sciences Limited
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of this study is 1) to investigate how safe and tolerable SUVN-I6107 is after a single oral dose at increasing dose levels and multiple oral doses at increasing dose levels, 2) to determine the pharmacokinetic (PK) profile after single and multiple ascending oral doses, 3) to investigate the effects of food on SUVN-I6107 pharmacokinetics and 4) to evaluate the pharmacodynamic (PD) effects of single and multiple ascending oral doses of SUVN-I6107 on quantitative electroencephalogram (qEEG) and event-related potential (ERP) assessments.

Timeline

Start
2025-01-07
Primary completion
2025-12-02
Completion
2025-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SUVN-I6107 Unknown — Oral

Indications

No indication recorded.